Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A. Jones, John C. Byrd, Jalaja Potluri et al.|The Lancet Oncology|2017Cited by 378
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, William G. Wierda, Barbara Eichhorst et al.|Journal of Clinical Oncology|2018Cited by 313
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W. Roberts, John F. Seymour, Shuo Ma et al.|Blood|2019Cited by 175
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutré, Matthew S. Davids, Michael Y. Choi et al.|Blood|2018Cited by 132
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapyAnthony R. Mato, John C. Byrd, William G. Wierda et al.|Haematologica|2019Cited by 40